日本癌症生物标记市场报告（按分析技术、生物分子、癌症类型、应用、最终用户和地区划分，2026-2034）

2025年，日本癌症生物标记市场规模达13.929亿美元。展望未来， IMARC Group预计到2034年，该市场规模将达到36.36亿美元，2026年至2034年间的复合年增长率（CAGR）为11.25%。癌症病例的不断增加，以及对有效诊断和监测工具日益增长的需求（这些工具能够显着提高治疗成功率和改善患者预后），是推动市场成长的主要因素。

本报告解答的关键问题：

• 日本癌症生物标记市场目前表现如何？未来几年又将如何发展？
• 新冠疫情对日本癌症生物标记市场产生了哪些影响？
• 日本癌症生物标记市场依分析技术分類的组成是怎样的？
• 日本癌症生物标记市场依生物分子类型分類的组成是怎样的？
• 日本癌症生物标记市场按癌症类型分類的组成是怎样的？
• 日本癌症生物标记市场按应用领域分類的组成是怎样的？
• 日本癌症生物标记市场以最终用户分類的组成是怎样的？
• 日本癌症生物标记市场价值链的各个阶段有哪些？
• 日本癌症生物标记研究的关键驱动因素和挑战是什么？
• 日本癌症生物标记市场的结构是怎么样的？主要参与者有哪些？
• 日本癌症生物标记市场的竞争程度如何？

目录

第一章：序言

第二章：范围与方法

• 研究目标
• 利害关係人
• 数据来源
• 市场估算
• 预测方法

第三章：执行概要

第四章：日本癌症生物标记市场－引言

• 概述
• 市场动态
• 产业趋势
• 竞争情报

第五章：日本癌症生物标记市场概况

• 历史及当前市场趋势（2020-2025）
• 市场预测（2026-2034）

第六章：日本癌症生物标记市场－依分析技术划分

• Omic Technologies
• 影像技术
• 免疫测定
• 细胞遗传学

第七章：日本癌症生物标记市场－依生物分子类型划分

• 基因生物标记
• 蛋白质生物标记
• 糖生物标记

第八章：日本癌症生物标记市场－以癌症类型划分

• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 胃癌
• 其他的

第九章：日本癌症生物标记市场－按应用领域划分

• 诊断
• 预后
• 风险评估
• 药物发现与开发
• 其他的

第十章：日本癌症生物标记市场－以最终用户划分

• 医院
• 学术和研究机构
• 门诊手术中心
• 诊断实验室
• 其他的

第十一章：日本癌症生物标记市场－按地区划分

• 关东地区
• 关西/近畿地区
• 中部/中部地区
• 九州·冲绳地区
• 东北部地区
• 中国地区
• 北海道地区
• 四国地区

第十二章：日本癌症生物标记市场－竞争格局

• 概述
• 市场结构
• 市场参与者定位
• 最佳制胜策略
• 竞争格局分析
• 公司评估象限

第十三章：关键参与者简介

第十四章：日本癌症生物标记市场－产业分析

• 驱动因素、限制因素和机会
• 波特五力分析
• 价值链分析

第十五章：附录

Japan cancer biomarkers market size reached USD 1,392.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,636.0 Million by 2034, exhibiting a growth rate (CAGR) of 11.25% during 2026-2034. The increasing cases of cancer, coupled with the rising need for effective diagnostic and monitoring tools to significantly improve the chances of successful treatment and better patient outcomes, are driving the market.

Cancer biomarkers are molecules or substances found in the body that can indicate the presence of cancer or provide information about its characteristics. These biomarkers are typically detected through blood tests, tissue samples, or imaging studies. They play a crucial role in cancer diagnosis, prognosis, and treatment. Biomarkers can include proteins, genes, hormones, or even specific cellular changes. By analyzing their levels or activity, healthcare professionals can identify the type of cancer, its stage, and its potential aggressiveness. This information helps in tailoring treatment plans, monitoring disease progression, and assessing treatment effectiveness. Cancer biomarkers also have a significant impact on personalized medicine, enabling doctors to choose the most appropriate therapies for individual patients. Additionally, they aid in cancer research, facilitating the development of new drugs and therapies. Overall, cancer biomarkers are essential tools in the fight against cancer, contributing to early detection, precise treatment, and improved patient outcomes.

Japan Cancer Biomarkers Market Trends:

The cancer biomarkers market in Japan is driven by several key factors that collectively contribute to its growth and significance in the field of oncology. Firstly, advancements in molecular biology and genomics have paved the way for the identification of novel biomarkers that can aid in early cancer detection and prognosis. Moreover, the increasing prevalence of cancer in Japan is a major driver, as there is a growing need for accurate and efficient diagnostic tools to combat this regional health challenge. Furthermore, the development of targeted therapies and personalized medicine approaches has accentuated the demand for biomarkers. These biomarkers assist in tailoring treatment plans to individual patients, improving the overall efficacy of cancer treatments while minimizing adverse effects. Additionally, the rise in R&D activities in the pharmaceutical and biotechnology sectors has spurred investments in biomarker discovery and validation, further propelling market growth. Moreover, the widespread adoption of liquid biopsy techniques for non-invasive biomarker detection, as they offer a less invasive alternative to traditional tissue biopsies, is expected to drive the cancer biomarkers market in Japan during the forecast period.

Japan Cancer Biomarkers Market Segmentation:

Profiling Technology Insights:

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics

Biomolecule Insights:

• Genetic Biomarkers
• Protein Biomarkers
• Glyco-Biomarkers

Cancer Type Insights:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Others

Application Insights:

• Diagnostics
• Prognostics
• Risk Assessment
• Drug Discovery and Development
• Others

End User Insights:

• Hospitals
• Academic and Research Institutions
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan cancer biomarkers market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan cancer biomarkers market?
• What is the breakup of the Japan cancer biomarkers market on the basis of profiling technology?
• What is the breakup of the Japan cancer biomarkers market on the basis of biomolecule?
• What is the breakup of the Japan cancer biomarkers market on the basis of cancer type?
• What is the breakup of the Japan cancer biomarkers market on the basis of application?
• What is the breakup of the Japan cancer biomarkers market on the basis of end user?
• What are the various stages in the value chain of the Japan cancer biomarkers market?
• What are the key driving factors and challenges in the Japan cancer biomarkers?
• What is the structure of the Japan cancer biomarkers market and who are the key players?
• What is the degree of competition in the Japan cancer biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Biomarkers Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Cancer Biomarkers Market Landscape

• 5.1 Historical and Current Market Trends (2020-2025)
• 5.2 Market Forecast (2026-2034)

6 Japan Cancer Biomarkers Market - Breakup by Profiling Technology

• 6.1 Omic Technologies
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2020-2025)
  • 6.1.3 Market Forecast (2026-2034)
• 6.2 Imaging Technologies
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2020-2025)
  • 6.2.3 Market Forecast (2026-2034)
• 6.3 Immunoassays
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2020-2025)
  • 6.3.3 Market Forecast (2026-2034)
• 6.4 Cytogenetics
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2020-2025)
  • 6.4.3 Market Forecast (2026-2034)

7 Japan Cancer Biomarkers Market - Breakup by Biomolecule

• 7.1 Genetic Biomarkers
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2020-2025)
  • 7.1.3 Market Forecast (2026-2034)
• 7.2 Protein Biomarkers
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2020-2025)
  • 7.2.3 Market Forecast (2026-2034)
• 7.3 Glyco-Biomarkers
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2020-2025)
  • 7.3.3 Market Forecast (2026-2034)

8 Japan Cancer Biomarkers Market - Breakup by Cancer Type

• 8.1 Breast Cancer
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2020-2025)
  • 8.1.3 Market Forecast (2026-2034)
• 8.2 Lung Cancer
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2020-2025)
  • 8.2.3 Market Forecast (2026-2034)
• 8.3 Colorectal Cancer
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2020-2025)
  • 8.3.3 Market Forecast (2026-2034)
• 8.4 Prostate Cancer
  • 8.4.1 Overview
  • 8.4.2 Historical and Current Market Trends (2020-2025)
  • 8.4.3 Market Forecast (2026-2034)
• 8.5 Stomach Cancer
  • 8.5.1 Overview
  • 8.5.2 Historical and Current Market Trends (2020-2025)
  • 8.5.3 Market Forecast (2026-2034)
• 8.6 Others
  • 8.6.1 Historical and Current Market Trends (2020-2025)
  • 8.6.2 Market Forecast (2026-2034)

9 Japan Cancer Biomarkers Market - Breakup by Application

• 9.1 Diagnostics
  • 9.1.1 Overview
  • 9.1.2 Historical and Current Market Trends (2020-2025)
  • 9.1.3 Market Forecast (2026-2034)
• 9.2 Prognostics
  • 9.2.1 Overview
  • 9.2.2 Historical and Current Market Trends (2020-2025)
  • 9.2.3 Market Forecast (2026-2034)
• 9.3 Risk Assessment
  • 9.3.1 Overview
  • 9.3.2 Historical and Current Market Trends (2020-2025)
  • 9.3.3 Market Forecast (2026-2034)
• 9.4 Drug Discovery and Development
  • 9.4.1 Overview
  • 9.4.2 Historical and Current Market Trends (2020-2025)
  • 9.4.3 Market Forecast (2026-2034)
• 9.5 Others
  • 9.5.1 Historical and Current Market Trends (2020-2025)
  • 9.5.2 Market Forecast (2026-2034)

10 Japan Cancer Biomarkers Market - Breakup by End User

• 10.1 Hospitals
  • 10.1.1 Overview
  • 10.1.2 Historical and Current Market Trends (2020-2025)
  • 10.1.3 Market Forecast (2026-2034)
• 10.2 Academic and Research Institutions
  • 10.2.1 Overview
  • 10.2.2 Historical and Current Market Trends (2020-2025)
  • 10.2.3 Market Forecast (2026-2034)
• 10.3 Ambulatory Surgical Centers
  • 10.3.1 Overview
  • 10.3.2 Historical and Current Market Trends (2020-2025)
  • 10.3.3 Market Forecast (2026-2034)
• 10.4 Diagnostic Laboratories
  • 10.4.1 Overview
  • 10.4.2 Historical and Current Market Trends (2020-2025)
  • 10.4.3 Market Forecast (2026-2034)
• 10.5 Others
  • 10.5.1 Historical and Current Market Trends (2020-2025)
  • 10.5.2 Market Forecast (2026-2034)

11 Japan Cancer Biomarkers Market - Breakup by Region

• 11.1 Kanto Region
  • 11.1.1 Overview
  • 11.1.2 Historical and Current Market Trends (2020-2025)
  • 11.1.3 Market Breakup by Profiling Technology
  • 11.1.4 Market Breakup by Biomolecule
  • 11.1.5 Market Breakup by Cancer Type
  • 11.1.6 Market Breakup by Service
  • 11.1.7 Market Breakup by End User
  • 11.1.8 Key Players
  • 11.1.9 Market Forecast (2026-2034)
• 11.2 Kansai/Kinki Region
  • 11.2.1 Overview
  • 11.2.2 Historical and Current Market Trends (2020-2025)
  • 11.2.3 Market Breakup by Profiling Technology
  • 11.2.4 Market Breakup by Biomolecule
  • 11.2.5 Market Breakup by Cancer Type
  • 11.2.6 Market Breakup by Service
  • 11.2.7 Market Breakup by End User
  • 11.2.8 Key Players
  • 11.2.9 Market Forecast (2026-2034)
• 11.3 Central/ Chubu Region
  • 11.3.1 Overview
  • 11.3.2 Historical and Current Market Trends (2020-2025)
  • 11.3.3 Market Breakup by Profiling Technology
  • 11.3.4 Market Breakup by Biomolecule
  • 11.3.5 Market Breakup by Cancer Type
  • 11.3.6 Market Breakup by Service
  • 11.3.7 Market Breakup by End User
  • 11.3.8 Key Players
  • 11.3.9 Market Forecast (2026-2034)
• 11.4 Kyushu-Okinawa Region
  • 11.4.1 Overview
  • 11.4.2 Historical and Current Market Trends (2020-2025)
  • 11.4.3 Market Breakup by Profiling Technology
  • 11.4.4 Market Breakup by Biomolecule
  • 11.4.5 Market Breakup by Cancer Type
  • 11.4.6 Market Breakup by Service
  • 11.4.7 Market Breakup by End User
  • 11.4.8 Key Players
  • 11.4.9 Market Forecast (2026-2034)
• 11.5 Tohoku Region
  • 11.5.1 Overview
  • 11.5.2 Historical and Current Market Trends (2020-2025)
  • 11.5.3 Market Breakup by Profiling Technology
  • 11.5.4 Market Breakup by Biomolecule
  • 11.5.5 Market Breakup by Cancer Type
  • 11.5.6 Market Breakup by Service
  • 11.5.7 Market Breakup by End User
  • 11.5.8 Key Players
  • 11.5.9 Market Forecast (2026-2034)
• 11.6 Chugoku Region
  • 11.6.1 Overview
  • 11.6.2 Historical and Current Market Trends (2020-2025)
  • 11.6.3 Market Breakup by Profiling Technology
  • 11.6.4 Market Breakup by Biomolecule
  • 11.6.5 Market Breakup by Cancer Type
  • 11.6.6 Market Breakup by Service
  • 11.6.7 Market Breakup by End User
  • 11.6.8 Key Players
  • 11.6.9 Market Forecast (2026-2034)
• 11.7 Hokkaido Region
  • 11.7.1 Overview
  • 11.7.2 Historical and Current Market Trends (2020-2025)
  • 11.7.3 Market Breakup by Profiling Technology
  • 11.7.4 Market Breakup by Biomolecule
  • 11.7.5 Market Breakup by Cancer Type
  • 11.7.6 Market Breakup by Service
  • 11.7.7 Market Breakup by End User
  • 11.7.8 Key Players
  • 11.7.9 Market Forecast (2026-2034)
• 11.8 Shikoku Region
  • 11.8.1 Overview
  • 11.8.2 Historical and Current Market Trends (2020-2025)
  • 11.8.3 Market Breakup by Profiling Technology
  • 11.8.4 Market Breakup by Biomolecule
  • 11.8.5 Market Breakup by Cancer Type
  • 11.8.6 Market Breakup by Service
  • 11.8.7 Market Breakup by End User
  • 11.8.8 Key Players
  • 11.8.9 Market Forecast (2026-2034)

12 Japan Cancer Biomarkers Market - Competitive Landscape

• 12.1 Overview
• 12.2 Market Structure
• 12.3 Market Player Positioning
• 12.4 Top Winning Strategies
• 12.5 Competitive Dashboard
• 12.6 Company Evaluation Quadrant

13 Profiles of Key Players

• 13.1 Company A
  • 13.1.1 Business Overview
  • 13.1.2 Product Portfolio
  • 13.1.3 Business Strategies
  • 13.1.4 SWOT Analysis
  • 13.1.5 Major News and Events
• 13.2 Company B
  • 13.2.1 Business Overview
  • 13.2.2 Product Portfolio
  • 13.2.3 Business Strategies
  • 13.2.4 SWOT Analysis
  • 13.2.5 Major News and Events
• 13.3 Company C
  • 13.3.1 Business Overview
  • 13.3.2 Product Portfolio
  • 13.3.3 Business Strategies
  • 13.3.4 SWOT Analysis
  • 13.3.5 Major News and Events
• 13.4 Company D
  • 13.4.1 Business Overview
  • 13.4.2 Product Portfolio
  • 13.4.3 Business Strategies
  • 13.4.4 SWOT Analysis
  • 13.4.5 Major News and Events
• 13.5 Company E
  • 13.5.1 Business Overview
  • 13.5.2 Product Portfolio
  • 13.5.3 Business Strategies
  • 13.5.4 SWOT Analysis
  • 13.5.5 Major News and Events

14 Japan Cancer Biomarkers Market - Industry Analysis

• 14.1 Drivers, Restraints, and Opportunities
  • 14.1.1 Overview
  • 14.1.2 Drivers
  • 14.1.3 Restraints
  • 14.1.4 Opportunities
• 14.2 Porters Five Forces Analysis
  • 14.2.1 Overview
  • 14.2.2 Bargaining Power of Buyers
  • 14.2.3 Bargaining Power of Suppliers
  • 14.2.4 Degree of Competition
  • 14.2.5 Threat of New Entrants
  • 14.2.6 Threat of Substitutes
• 14.3 Value Chain Analysis

15 Appendix